The U.S. Food and Drug Administration (FDA) has granted 510 (k) clearance to a standalone lateral lumbar interbody fusion device from the internationally renowned surgeon Randal Betz, M.D.’s company, ...

BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 3Q 2024 financial results and while a company at this stage is far more reliant on testing of products, ...

The University of Oxford has been awarded part of a £2 million grant to study whether tick proteins could replace the need for immunosuppressant drugs in people undergoing treatments for type 1 ...

It also reviews the results of the various interventions to facilitate the surgeon in choosing the appropriate treatment option for any given patient. Degenerative spondylolisthesis is believed to ...

A new clinical practice guideline developed by the American Academy of Sleep Medicine provides updated recommendations for ...

Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as ...

And that initial $1.15 billion NIH got for the RECOVER program — which stands for Researching COVID to Enhance Recovery — has yielded few answers and zero approved treatments so far. “ ...

Teclistamab is recommended as an option for treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome ...

Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help people struggling with alcohol and opioid addiction, according to a new study published Thursday in the scientific ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded as ...